Compare
Abbott Laboratories vs Penumbra (ABT vs PEN)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Abbott Laboratories (ABT) returned -11.7% and Penumbra (PEN) +41.5%; so far this year the figures are -12.3% and +2.7%.
Abbott Laboratories is the larger company by market value, about 15.1 times the size of Penumbra.
On trailing earnings, ABT trades at 40.9 times and PEN at 80.4 times.
Revenue grew +10.0% at ABT and +17.0% at PEN over the last year.
ABT yields 2.29%. PEN pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABT | PEN | |
|---|---|---|
| Price | $109.93 | $319.21 |
| 1-day | -3.23% | -0.59% |
| YTD | -12.26% | +2.67% |
| 1 year | -11.73% | +41.53% |
| 3 years | +15.70% | +64.49% |
| Market cap | $190.4B | $12.6B |
| P/E | 40.9 | 80.4 |
| P/S | 3.95 | 8.06 |
| P/B | 3.73 | 7.95 |
| Revenue growth | +10.00% | +17.00% |
| EPS growth | -66.20% | -5.30% |
| Gross margin % | 56.9 | 68.0 |
| Net margin % | 9.7 | 10.1 |
| ROE % | 9.2 | 9.9 |
| Debt / equity | 0.61 | 0.00 |
| FCF yield % | 3.5 | 1.6 |
| Dividend yield % | 2.29 | — |
| Beta | 0.06 | 0.11 |
| RSI (14) | 58.5 | 45.9 |
| Technical rating |